Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2E1 | P05181 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13413594 | 1.00 | CYP2E1 (0.35) | CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL13413286 | 0.81 | KMT2A (0.42) | NPC1GAAHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL15743987 | 0.81 | P2RX7 (0.31) | CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL15744006 | 0.81 | P2RX7 (0.31) | CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL22222423 | 0.79 | P2RX7 (0.32) | CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL20780465 | 0.77 | P2RX7 (0.34) | P2RX7 | |
| SCHEMBL20780466 | 0.77 | P2RX7 (0.34) | P2RX7 | |
| SCHEMBL13394926 | 0.77 | P2RX7 (0.31) | P2RX7 | |
| SCHEMBL13413288 | 0.77 | CYP3A4 (0.42) | CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL13413592 | 0.77 | CYP3A4 (0.42) | CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210290623-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2021-09-23 | — | — | US | disclosed |
| US-20100099716-A1 | CETP INHIBITORS | MERCK SHARP & DOHME LLC | 2010-04-22 | — | — | US | disclosed |
| US-7652049-B2 | 1-benzyl-4-[4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]imidazolidin-2-one; cholesteryl ester transfer protein inhibitor; raising HDL-cholesterol, reducing LDL-cholesterol; atherosclerosis; antiinflammatory agent; synergistic mixture with other active ingredients | MERCK & CO., INC. (US) | 2010-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210290623-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | HMGCR, PCSK9, FABP3 | CYP2E1 1687/4885CYP3A4 1395/4885CYP2A6 719/4885 |
| US-20100099716-A1 | CETP INHIBITORS | CETP, APOB, MTTP | CYP2E1 367/4885CYP3A4 446/4885CYP2A6 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.